SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chan HL, Ku G, Khoo OT. Allopurinol associated hypersensitivity reactions: cutaneous and renal manifestations. Aust N Z J Med 1977; 7: 51822.
  • 2
    McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981; 40: 2459.
  • 3
    Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 827.
  • 4
    Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al, for the EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 2532.
  • 5
    Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 16007.
  • 6
    Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 33743.
  • 7
    Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 41349.
  • 8
    Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al, for the JSAR Research Group. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 161722.
  • 9
    Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 7049.
  • 10
    Clark W, Hulbert M. Research issues: dually eligible Medicare and Medicaid beneficiaries, challenges and opportunities. Health Care Financ Rev 1998; 20: 110.
  • 11
    Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 2007; 45: 121620.
  • 12
    Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Stolley PD, et al. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991; 10: 56576.
  • 13
    Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 437.
  • 14
    Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Shaw M, et al. A population-based study of Stevens-Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991; 127: 8318.
  • 15
    Schneider G, Kachroo S, Jones N, Crean S, Avetisyan R, Reynolds M. Mini-Sentinel systematic evaluation of health outcome of interest definitions for studies using administrative data: erythema multiforme major/minor/not otherwise specified, Stevens-Johnson syndrome, or toxic epidermal necrolysis report. 2010. URL: http://www.mini-sentinel.org/work_products/HealthOutcomes/Mini-Sentinel-HOI-Evidence-Review-Erythema-Multiforme-Report.pdf.
  • 16
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 6139.
  • 17
    Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001; 154: 85464.
  • 18
    Schneeweiss S. A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 2010; 19: 85868.
  • 19
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 91520.
  • 20
    D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 226581.
  • 21
    Cox D. Regression models and life-tables. J R Stat Soc 1972; 34: 187220.
  • 22
    Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, for the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 14537.
  • 23
    Fritsch P. European Dermatology Forum: skin diseases in Europe. Skin diseases with a high public health impact: toxic epidermal necrolysis and Stevens-Johnson syndrome. Eur J Dermatol 2008; 18: 2167.
  • 24
    Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011; 63: 10210.
  • 25
    Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009; 61: 88592.
  • 26
    Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 17080.
  • 27
    Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F9917.
  • 28
    Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis salt-sensitivity. Hypertension 2002; 40: 35560.
  • 29
    Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 11016.
  • 30
    Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002; 283: F110510.
  • 31
    Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension. JAMA 2008; 300: 92432.
  • 32
    Strom B. Overview of automated databases in pharmacoepidemiology. In: Strom B, Kimmel S, editors. Textbook of pharmacoepidemiology. Chichester (UK): John Wiley & Sons; 2006. p. 16771.
  • 33
    Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 2002; 69: 594608.
  • 34
    Sloan RW. Hyperuricemia and gout. J Fam Pract 1982; 14: 9236.
  • 35
    Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. Am J Kidney Dis 2005; 46: 22532.
  • 36
    Chan SH, Tan T. HLA and allopurinol drug eruption. Dermatologica 1989; 179: 323.
  • 37
    Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 356772.
  • 38
    Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 31723.
  • 39
    Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al, for the RegiSCAR Study Group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99107.